Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193689 | 0.84 | ATM (0.41) | L3MBTL1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4198386 | 0.84 | L3MBTL1 (0.42) | L3MBTL1MEN1KMT2AKDM4EPOLB | |
| SCHEMBL4186785 | 0.81 | L3MBTL1 (0.48) | L3MBTL1MEN1KMT2APOLBTSHR | |
| SCHEMBL4184867 | 0.80 | HTR1A (0.40) | L3MBTL1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL4186778 | 0.77 | L3MBTL1 (0.48) | L3MBTL1MEN1KMT2AKDM4EPOLB | |
| SCHEMBL8488474 | 0.77 | L3MBTL1 (0.48) | L3MBTL1MEN1KMT2APOLBTSHR | |
| SCHEMBL3818013 | 0.76 | L3MBTL1 (0.55) | L3MBTL1MEN1KMT2APOLBTSHR | |
| SCHEMBL3056303 | 0.74 | KDM4E (0.46) | L3MBTL1MEN1KMT2AKDM4ETSHR | |
| SCHEMBL4493204 | 0.74 | USP2 (0.64) | L3MBTL1KDM4ETSHRHSD17B10ALDH1A1 | |
| SCHEMBL4509344 | 0.74 | USP2 (0.64) | L3MBTL1KDM4ETSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686987-A4 | ADVANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080044881-A1 | Advanced Indolinone Based Protein Kinase Inhibitors | SCRIPPS RESEARCH INSTITUTE, THE | 2008-02-21 | — | — | US | disclosed |
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-12-21 | — | — | US | disclosed |
| EP-1686987-A2 | ADVANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005053614-A2 | ADVANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005053686-A1 | INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | PHKG1, PHKG2, PRKCH | L3MBTL1 2815/4885MEN1 4665/4885KMT2A 1643/4885 |
| US-20080044881-A1 | Advanced Indolinone Based Protein Kinase Inhibitors | PHKG1, PHKG2, HIPK1 | L3MBTL1 1974/4885MEN1 4193/4885KMT2A 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.